National Cancer Institute (nci)

This study tests whether adjusting chemotherapy doses for each patient can improve outcomes after a stem cell transplant for blood cancers caused by a RUNX1 gene mutation. Up to 98 people aged 4 to 70 with these cancers will receive a transplant from a half-matched donor. The goa…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …

This phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…

This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …

This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests a new combination for recurrent glioblastoma, a fast-growing brain tumor. The treatment pairs Actimab-A, a radioactive antibody that seeks out cancer cells, with cemiplimab, an immunotherapy that helps the immune system attack tumors. About 30 adults …

This phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This early-phase trial tests the safety and best dose of glofitamab, an antibody that helps the immune system attack cancer, when given alongside standard chemotherapy (R-CHOP and R-DHAP) for people with untreated mantle cell lymphoma. Sixteen adults aged 18 to 75 with stage II b…

This phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…

This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patien…

This study tests whether adding epoetin alfa or emavusertib to luspatercept helps people with low-risk myelodysplastic syndrome (MDS) and anemia. MDS is a bone marrow disorder that leads to low blood counts. The goal is to see if these combinations improve red blood cell producti…

This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery …

This early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…

This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to …

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This phase 2 trial tests whether two immunotherapy drugs, botensilimab and balstilimab, can clear tiny amounts of cancer DNA from the blood of people with stage II or III colorectal cancer who have completed standard treatment. The study enrolls 20 adults whose blood still shows …

This study tests adding a new drug, iberdomide, to standard chemoimmunotherapy for children and young adults (ages 1-30) whose neuroblastoma has returned, not responded, or worsened after prior treatment. The goal is to see if the combination is safe and works better at controlli…

This Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…

This study tests a vaccine called SurVaxM in 80 current or former heavy smokers at high risk for lung cancer. The vaccine trains the immune system to recognize and attack cells that produce a protein called survivin, which is common in cancer cells. The goal is to see if the vacc…

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation.…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…